Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 25, 2014

Study Completion Date

September 12, 2016

Conditions
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the Stomach
Interventions
DRUG

5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab

"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"

DRUG

Post-operative treatment trastuzumab mono therapy

"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"

Trial Locations (1)

D-68167

Tagestherapiezentrum am ITM & III. Medizinische Klinik Universitätsmedizin Mannheim, Mannheim

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT01472029 - Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | Biotech Hunter | Biotech Hunter